Additionally, the identification of HMG-CoA reductase inhibitors or “statins” (Cerivastatin, Pitavastatin, and Mevastatin) as potential therapeutic options is supported by studies not only in rodent models but also in ADPKD patients where statins diminished the severity of the disease47,48. The gene discussed is HMGCR; the disease is autosomal dominant polycystic kidney disease.